Outcome that came from the combined analysis of two European Phase II trials have been introduced at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat retrospective research ended up performed on serum samples from superior non-squamous non-small cell lung cancer (NSCLC) affected individuals handled together with the combination procedures bevacizumab plus erlotinib. Outcome confirmed the fact that VeriStrat test was capable of to identify affected individuals more likely to have better and worse survival consequences if treated with the mix therapy.
Pretreatment serum samples from 114 affected individuals handled by using bevacizumab plus erlotinib have been classified as either VeriStrat Good or VeriStrat Poor. The research confirmed there arised a statistically major change in overall survival among the two groups.
Researchers concluded that the VeriStrat test can be helpful for clinical decision-making, symbolizing a prognostic and possibly predictive biomarker for therapy by using erlotinib and erlotinib mixtures. Potential tests are ongoing, such as a Phase III trial in superior squamous cell lung cancer, sponsored by the European Thoracic Oncology Platform (ETOP).
No comments:
Post a Comment